Dutch promises take EMA closer to 'tailor-made' Amsterdam home

1 March 2018

The European Medicines Agency (EMA) has taken a step closer to formalizing its move to Amsterdam after accepting the pledge of the Dutch government that its brand new, tailor-made premises will be ready in the city by November 2019.

Currently headquartered in London, the agency will have to be fully operational in Amsterdam by March 30, 2019, when the UK is set to withdraw from the European Union (EU).

The agency will initially be placed in a temporary home in the Sloterdijk neighborhood of western Amsterdam while the permanent headquarters are being finished in the Zuidas, or Southern Axis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK